ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,110 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical IndustryBaselMonte Rosa Therapeutics AG
Monte Rosa Therapeutics AG Logo
Verified· 3 sources

Monte Rosa Therapeutics AG

Summary

About the company

The core activity of Monte Rosa Therapeutics is the discovery and development of medicines, particularly protein degraders (Protein-Targeting Chimeras, PROTACs), for the treatment of cancer and other diseases. The company focuses on developing small molecules that can specifically destroy proteins in the body, thereby preventing the progression of diseases.

AI-generated
Offering

Products & services

Industry:Pharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
✓ Offered
4
Development of molecular glue degraders
Development of molecular glue degraders for targeted protein degradation therapies, including preclinical and clinical programs against oncology, immunology and inflammatory diseases.
Oncology programs
Oncology programs with oral, selective MGD candidates against GSPT1 and CCNE1/CDK2, including studies and preclinical development in castration-resistant prostate cancer and CCNE1-amplified tumours.
Immunology and inflammation programs
Immunology and inflammation programs with MGD candidates against VAV1 and NEK7 for immune-mediated and IL-1β/NLRP3-driven diseases, spanning clinical, preclinical and collaborative development.
Drug discovery and development partnerships
Collaborations and licensing agreements to discover and develop MGD candidates against targets in cancer, neurological and immune-mediated diseases.
Press

Media

October 28, 2024Media
Monte-Rosa Therapeutics enters billion-dollar partnership with Novartis
startupticker.ch
June 25, 2021Media
Monte Rosa Therapeutics raises USD222 million in successful IPO
startupticker.ch
Comparisons

Monte Rosa Therapeutics AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Monte Rosa Therapeutics AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Monte Rosa Therapeutics AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Klybeckstrasse 191
4057 Basel

At a glance

Legal form
Corporation
UID
CHE-405.675.696
Founded
2018 · 8 years
Last commercial register change
March 13, 2026
Employees
21 to 50

Knowledge

No knowledge articles yet

Once Monte Rosa Therapeutics AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started

Similar companies

ST
Skyhawk Therapeutics Europe GmbH
Basel
MB
Myria Biosciences AG
Basel
BA
BioVersys AG
Basel
LT
LifeMine Therapeutics (Switzerland) GmbH
Basel
RP
Rhizen Pharmaceuticals AG
Basel
FT
FoRx Therapeutics AG
Basel
ET
EraCal Therapeutics AG
Basel
AA
Adagene AG
Basel